Program

G6PD Workshop

• Welcome Addresses
• Session 1: The Problem:
• Safe Primaquine dosing in the treatment of P.vivax: the role of G6PD deficiency
• The P. vivax endemicity map
• G6PD deficiency: prevalence, mutations, and haemolytic risk in the Asia Pacific region
• Primaquine & G6PD testing in P. vivax treatment: The WHO strategy
• Session 2: G6PD Testing:
• Overview of experimental and standard methods to diagnose G6PD deficiency
• Phenotypic assays: the experience from Mae Sot
• RDTs: the experience from Cambodia
• Session 3: APMEN Country Experiences:
• G6PD testing in Philippines
• G6PD testing in Indonesia
• Session 4: Research Priorities:
• Where do we go from here? Research priorities
• Industries perspective: what resources do they use in the development of tafenoquine? How can G6PDd testing be applied to clinical trials?
• Validation trials, and defining standards for new G6PD tests
• When is G6PD testing cost-effective?
• Summary and Day 1 Closing

APMEN Vivax Working Group Business Meeting

Vivax Working Group Meeting

• Welcome and Overview
• Session 1: Overview to P.vivax Genotyping: 
• P.vivax genotyping: utilities and the VxWG multi-centre genotyping project
• The Papua New Guinea Experience
• Session 2: APMEN Country Experiences:
• Update from Republic of Korea
• Update from China
• Update from Indonesia
• Update from Sri Lanka
• Session 3: A Regional Perspective:
• P.vivax Genetic Mapping in the Asia Pacific Region
• Molecular Data Sharing – WWARN experience
• Open Discussion – Data Sharing
• Session 4: Prospects for whole genome sequencing:
• P. vivax genome sequencing: update
• P. vivax genome sequencing challenges and prospects – progress update

Meeting Materials

• Meeting Agenda
• Business Meeting Minutes
• Malaria Journal (2013, 12:112): Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report.